Novel Antiviral Strategies in the Treatment of COVID-19: A Review.
Novel Antiviral Strategies in the Treatment of COVID-19: A Review.
复制标题
DOI：
10.3390/microorganisms8091259
复制
发表时间：
2020-08-20
期刊：
影响因子：
4.5
通讯作者：
Chen YC
中科院分区：
文献类型：
--
作者：
Chen SJ;Wang SC;Chen YC
由严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）大流行仍然是人类的全球公共卫生问题。迄今为止，它已在全球造成超过1000万例感染和50多万例死亡。许多科学家已经尽了最大努力来发现治疗这种疾病的安全有效的药物;然而，市场上仍然没有批准的标准疗法或有效的抗病毒药物。许多新药正在开发中，而几种最初适用于或拟用于其他疾病的传统药物很可能对治疗COVID-19有效，但其安全性和疗效存在争议，正在研究中，或处于临床试验阶段。幸运的是，一些新的抗病毒策略，如恢复期血浆、成簇规则间隔短回文重复序列（CRISPR）和间充质干细胞（MSC）疗法，可能为COVID-19患者提供额外或替代选择或同情使用，特别是重症患者，尽管其安全性和有效性也在研究中。在这篇综述中，我们分别探讨了恢复期血浆、CRISPR和MSC疗法在COVID-19治疗中的应用、可能机制和成功病例的疗效。此外，这些新的抗病毒策略的前景和局限性进行了评估。
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS–CoV-2), is still a global public health problem for humans. It has caused more than 10,000,000 infections and more than 500,000 deaths in the world so far. Many scientists have tried their best to discover safe and effective drugs for the treatment of this disease; however, there are still no approved standard therapeutics or effective antiviral drugs on the market. Many new drugs are being developed, and several traditional drugs that were originally indicated or proposed for other diseases are likely to be effective in treating COVID-19, but their safety and efficacy are controversial, under study, or in clinical trial phases. Fortunately, some novel antiviral strategies, such as convalescent plasma, clustered regularly interspaced short palindromic repeats (CRISPR), and mesenchymal stem cell (MSC) therapy, potentially offer an additional or alternative option or compassionate use for the people suffering from COVID-19, especially for critically ill patients, although their safety and efficacy are also under study. In this review, we explore the applications, possible mechanisms, and efficacy in successful cases using convalescent plasma, CRISPR, and MSC therapy for COVID-19 treatment, respectively. Furthermore, the perspectives and limitations of these novel antiviral strategies are evaluated.
登录
查看更多内容
影响因子：
--
作者：
Corman VM;Muth D;Niemeyer D;Drosten C
通讯作者：
Drosten C
DOI：
10.1007/s10096-004-1271-9
发表时间：
2005-01
期刊：
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
影响因子：
--
作者：
Cheng Y;Wong R;Soo YO;Wong WS;Lee CK;Ng MH;Chan P;Wong KC;Leung CB;Cheng G
通讯作者：
Cheng G
影响因子：
9.7
作者：
Chen, Minjiang;Mao, Aiwu;Ji, Jiansong
通讯作者：
Ji, Jiansong
影响因子：
7.6
作者：
Caly, Leon;Druce, Julian D;Wagstaff, Kylie M
通讯作者：
Wagstaff, Kylie M
DOI：
10.26355/eurrev_202004_20875
发表时间：
2020-04-01
影响因子：
3.3
作者：
Diurno, F.;Numis, F. G.;Facchini, G.
通讯作者：
Facchini, G.